We aim to understand why some people are more likely than others to develop type 2 diabetes and related conditions such as obesity. We combine genetic, molecular and clinical data to find clues to disease mechanisms that will lead to more effective strategies for prevention and treatment.
Type 2 diabetes and obesity are major contributors to disease and premature death across the globe, yet effective strategies for prevention and treatment remain limited.
Our group starts by comparing the genome sequences of large numbers of individuals to pinpoint those DNA sequence variants that contribute to disease predisposition. To understand how these variants influence disease risk, we perform studies in cells and humans, with a major focus on the insulin producing beta-cells in the pancreas. Then, we exploit this information to develop new ways of treating and preventing disease, for example by highlighting new targets for drug development or exposing environmental factors amenable to lifestyle modification.
We are based at both the Oxford Centre for Diabetes, Endocrinology and Metabolism and the Wellcome Trust Centre for Human Genetics, and work very closely with other Oxford researchers with related interests particularly Prof Anna Gloyn. Much of our research involves large-scale consortium studies made possible by the coordinated effort of over 1000 colleagues in more than 50 countries.
We are members of over 20 international consortia including:
Recent lab Alumni
Nicola Beer (NovoNordisk)
Martijn van de Bunt (NovoNordisk)
Karina Barasik (DTU, Copenhagen)
Kyle Gaulton (Univ California San Diego)
Thorhildur Juliusdottir (DeCODE, Reykjavik)
Loukas Moutsianas (Sanger Institute)
Manny Rivas (Stanford)
Clinical studies and trials
We are involved in multiple clinical studies including:
- DIRECT (IMI-funded effort to identify biomarkers for diabetes progression)
- STEMBANCC (IMI-funded effort to develop stem-cell derived disease models)
- RHAPSODY (IMI-funded effort to identify biomarkers for diabetes progression)
- BEAT-DKD (IMI-funded effort to identify biomarkers for diabetic renal disease)
- DIVA (MRC-funded) experimental medicine)
- NIHR-BRC (Diabetes and Genomic Medicines Themes)
- Accelerating Medicines Partnership (AMPT2D)